Clinical Trial Update: Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating low-dose pegylated interferon plus ribavirin to prevent hepatocellular carcinoma recurrence after surgical resection in patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: Kyoto University | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED